PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
November 30, 2025Nature Communications3 citationsOpen Access

Orphan broadly RBD-binding antibodies annotate three remaining conserved RBD epitopes along SARS-CoV-2 evolution

View Full Paper
MXMinxiang XieYQYinong QiuXZXiaoyu Zhao

Key Points

  • Passive transfer of broadly binding antibodies reduced viral infection in a hamster model, suggesting therapeutic potential.
  • Structural analyses indicate that these antibodies mainly target conserved regions of the spike protein, highlighting significant immunogenic sites.
  • Vaccination strategies must consider the evolution of SARS-CoV-1 and emerging variants to maintain efficacy against future infections.
  • Somatic hypermutation levels in these antibodies reflect their adaptive response to SARS-CoV-2's antibody evasion tactics.

Abstract

The receptor-binding domain (RBD) of the SARS-CoV-2 spike (S) protein continues to evolve, facilitating antibody evasion. It remains unclear whether any conserved RBD epitopes persist across SARS-CoV-2 variants and whether vaccination and/or breakthrough infection (BTI) can elicit antibodies capable of targeting these conserved regions to counter future variants. Here, using a heterogeneous double-bait single B-cell sorting strategy, we identify a subset of antibodies with broad-spectrum RBD binding, including recognition of SARS-CoV-1 and emerging variants such as EG.5.1, BA.2.86, JN.1, and KP.2/3. These broadly binding antibodies (bbAbs) exhibit elevated levels of somatic hypermutation but are infrequently derived from clonally expanded B lymphocytes. Passive transfer of representative bbAbs reduces viral infection in a male hamster model. Structural analyses reveals that these bbAbs primarily target three distinct, highly conserved RBD epitopes, suggesting potential regions of future mutational pressure and highlighting the presence of conserved and immunogenic RBD conformations that may serve as a foundation for the development of broadly protective vaccines.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Xie et al. (2025) studied this question.

synapsesocial.com/papers/692b94581d383f2b2a378fb5https://doi.org/10.1038/s41467-025-65596-0
Ask AI
Helpful
Bookmark
Share
View Full Paper